News
Zacks Investment Research on MSN10h
MRNA Beats on Q2 Earnings & Sales, Stock Down on Lowered Sales View
Moderna MRNA incurred a loss of $2.13 per share in the second quarter of 2025, narrower than the Zacks Consensus Estimate of ...
(NASDAQ:MRNA) today reported financial results and provided business updates for the second quarter of 2025. "In the last three months, we advanced our pipeline with positive Phase 3 flu vaccine ...
In a memo, CEO Stéphane Bancel said the job cuts are needed to align the struggling vaccine maker’s cost structure with the ...
Merck (MRK) may be a storied pharmaceutical giant with a 134-year history, but it still has a lot of room to run. Merck is ...
The Covid-19 pandemic turned Moderna and BioNTech into household names almost overnight. Now the two companies find ...
- Non-GAAP EPS of $2.13 topped estimates by $0.11 in Q2 2025; GAAP revenue of $15.8 billion missed by $93 million in Q2 2025. - KEYTRUDA oncology drug sales climbed 9% in Q2 2025, while GARDASIL ...
Zacks Investment Research on MSN3d
Moderna to Report Q2 Earnings: Is a Beat in Store for the Stock?
We expect Moderna MRNA to surpass expectations when it reports second-quarter 2025 earnings on Aug. 1, before the opening ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback